QR-Code

Bivalent RSVpreF Subunit Vaccine Safety and Immunogenicity in Seropositive 2–<18 Year Olds

<b>Background/Objectives:</b> We aimed to determine safe and immunogenic RSVpreF vaccine dose levels for further clinical development in 2–<18 year olds. <b>Methods:</b> The phase 1, age-descending, open-label Picasso trial evaluated different RSVpreF dose levels in respiratory syncytial virus (RSV)...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Julia Glanternik, Grant C. Paulsen, Shelly Senders, Michael Smith, Emma Shittu, Barbara A. Pahud, Lisa Pereira, Lesong Chen, Maria Maddalena Lino, Elena V. Kalinina, Danielle Baranova, Warren V. Kalina, Elie Needle, MaryAnn Murillo, John M. Leech, David Cooper, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Iona Munjal
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2026-01-01
Schriftenreihe:Vaccines
Schlagworte:
clinical trial
immunogenicity
pediatric
LRTI
RSV
RSVpreF
Online-Zugang:https://www.mdpi.com/2076-393X/14/2/128
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge